Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks. The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life). RESULTS A total of 364 patients were assigned to the tirzepatide group and 367 to the placebo group; the median duration of follow-up was 104 weeks. Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the SUMMIT trial (for tirzepatide) showed a reduction in events regarding time to cardiovascular death or worsening heart failure over 104 weeks (HR 0•62, 0•41-0•95), 79”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [79]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [30]
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“Tirzepatide also lowers CRP levels in clinical trials in people with heart failure with preserved ejection fraction, or OSA (19, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“In the SUMMIT trial (Study of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity), tirzepatide reduced the risk of the composite of cardiovascular death and worsening HF events.23”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [23]
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758
Self-citationPacker, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
Self-citationTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF
Savji, N., Meijers, W. C., Bartz, T. M., Bhambhani, V., Cushman, M., Nayor, M., Kizer, J. R., Sarma, A., Blaha, M. J., Gansevoort, R. T., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.05.018 · Cited by 499
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Self-citationPaulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 393
Self-citationKosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citation
Cited by
Items 101–200 of 1,086
Triple Agonism Based Therapies for Obesity
Goldney, J., Hamza, M., Surti, F., Davies, M. J., & Papamargaritis, D. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00770-z · Cited by 22
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
Mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF)
Pecchia, B., Samuel, R., Shah, V., Newman, E., & Gibson, G. T. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10504-3 · Cited by 26
“Intriguingly, the use of glucagon-like peptide 1 receptor (GLP-1) agonists, which were originally developed for the treatment of diabetes mellitus and obesity, have been shown to improve exercise capacity in patients with HFpEF [127, 128].”
Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence
Sattar, N. A., García‐Pérez, L., Rodríguez, Á., Kapoor, R., Stefański, A., & Hankosky, E. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16549 · Cited by 28
“39 Moreover, the pre-specified meta-analysis of 7 SURPASS trials demonstrated that tirzepatide had a similar point estimate for the risk of hospitalization for heart failure (hazard ratio: 0.67, 95% CI: 0.26 to 1.70) as the SUMMIT trial, accepting wide CIs due to smaller total event numbers.”
InfluentialZha, D., Gao, P. H., & Wu, X. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.114382 · Cited by 27
“In addition, tirzepatide is a promising therapeutic option for the treatment of heart failure that provides significant metabolic and cardiovascular benefits [93], including a reduced risk of death from cardiovascular diseases and deterioration of heart failure [94].”
Increasing the health span: unique role for exercise
Gaesser, G. A., Hall, S. E., Angadi, S. S., Poole, D. C., & Racette, S. B. (2025) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00049.2025 · Cited by 25
Bae, J. H., Haam, J.-H., Jeon, E. J., Kang, S. Y., Song, S., Park, C., & Kwon, H. (2025) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes25042 · Cited by 37
“80,81 These agents mitigate inflammation, 82 cardiac remodeling, 83,84 epicardial adipose tissue accumulation, 84 volume-pressure overload, 85 and cardiovascular or kidney injury.”
Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Barbagelata, L., Touzas, P., & Frías, J. P. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09991-4 · Cited by 21
Wu, J., Chan, S., Hsu, W., Kuo, C., Tsai, Y., Liu, T., Huang, P., Chuang, M., Yu, T., & Lai, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16353 · Cited by 22
“11 14 Among the six anti-obesity medications approved by the US Food and Drug Administration for long-term use (including GLP-1RAs [semaglutide and liraglutide], phentermine-topiramate, naltrexone-bupropion, orlistat and tirzepatide), tirzepatide has demonstrated the greatest weight loss effect.”
Landsteiner, I., Verwerft, J., Belov, D., Verbrugge, F. H., & Lewis, G. D. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag175 · Cited by 28
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 24
“The mean KCCQ-CSS was 53.5 points, the mean 6-min walk distance was 302.8 m, and 46.9% of patients had had a hospitalization or urgent care visit for worsening HF in the previous 12 months [62].”
InfluentialMarques, P. S., Travlos, C. K., Matias, P., Neves, J. S., Tsoukas, M. A., Mavrakanas, T. A., Joza, J. E., Ferreira, J. P., & Sharma, A. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102573 · Cited by 22
Epicardial Adipose Tissue—A Novel Therapeutic Target in Obesity Cardiomyopathy
Wiszniewski, K., Grudniewska, A., Szabłowska‐Gadomska, I., Pilichowska‐Paszkiet, E., Zaborska, B., Zgliczyński, W., Dudek, P., Bik, W., Sota, M., & Mrozikiewicz‐Rakowska, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167963 · Cited by 25
“Furthermore, evidence from the SUMMIT trial demonstrated that in obese patients with heart failure with preserved ejection fraction, tirzepatide reduces the risk of a composite endpoint involving heart failure exacerbation and cardiovascular death [162].”
Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?
Packer, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf645 · Cited by 28
“8,9 Might obesity and visceral adiposity also contribute to the pathogenesis of heart failure and a reduced ejection fraction (HFrEF)?”
InfluentialSelf-citationKeramida, K., López‐Fernández, T., Anker, M. S., Petrie, M. C., Ameri, P., Anderson, L. J., Bergler-Klein, J. K., Deswal, A. M., Farmakis, D. T., Ibáñez, B., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70005 · Cited by 24
2026 iCARDIO Alliance Global Implementation Guidelines on Heart Failure
Chopra, V., Abraham, W. T., Amir, O., Anker, S. D., Atherton, J. J., Bacal, F., von Bardeleben, R. S., Brito, D., Burgos, L. M., Butler, J., et al. (2025) · Global Cardiology · doi:10.4081/cardio.2025.70 · Cited by 23
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Apperloo, E. M., Heerspink, H. J. L., van Raalte, D. H., & Muskiet, M. H. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf110 · Cited by 25
“Survodutide, a GLP-1/glucagon co-agonist currently in phase 3 trials (SYNCHRO-NIZE) for obesity treatment, achieved up to 18.7% weight loss after 46 weeks of weekly dosing (0.6–4.8 mg) in phase 2 [58 ], although gastrointestinal AEs led to discontinuation rates of 20–29%.”
InfluentialFabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies
Thompson, S., Roy, A., Geberhiwot, T., Gehmlich, K., & Steeds, R. P. (2025) · Biomedicines · doi:10.3390/biomedicines13030624 · Cited by 24
Sallam, M., Snygg, J., Ghandour, S. E., & Sallam, M. (2025) · Obesities · doi:10.3390/obesities5020026 · Cited by 21
iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025
Chopra, V., Khan, M. S., Abdelhamid, M., Abraham, W. T., Amir, O., Anker, S. D., Atherton, J. J., Bacal, F., von Bardeleben, R. S., Brito, D. A., et al. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.05.094 · Cited by 34
Borlaug, B. A., Holse, C., Jung, M. H., Lincoff, A. M., Mulvagh, S. L., Stærk‐Østergaard, J., Tuttle, K. R., & Petrie, M. C. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102712 · Cited by 25
Self-citationViana, D. P. D. C., Invitti, A. L., & Schor, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110741 · Cited by 21
Obesity and its management in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Alvarez, J. A., Baker, J. C., Bruni, V., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Domenico, F. D., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109045 · Cited by 21
Zhou, X., Fan, Q.-Y., Targher, G., Byrne, C. D., Chen, Q., Shapiro, M. D., Dong, Y.-X., Sung, K., Lip, G. Y. H., Lazarus, J. V., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3193-9 · Cited by 27
“These functional and structural changes may also contribute to left ventricular diastolic dysfunction and increase the risk of new-onset heart failure, particularly heart failure with preserved ejection fraction (HFpEF) (Salah et al., 2021; Zhou et al., 2024c).”
InfluentialSiddiqi, T. J., Khan, M. S., Waqas, S. A., Spall, H. G. C. V., Shapiro, M. D., Fonarow, G. C., Januzzi, J. L., Afzal, A. M., Pandey, A., Butler, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70048 · Cited by 20
“1 8, 1 9,23 Significant weight loss may also lead to muscle wasting and frailty, potentially increasing the risk of falls and fractures, particularly in older populations.”
Lund, L. H., Maggioni, A. P., Crespo-Leiro, M. G., Laroche, C., Gotsman, I., Pojskić, B., Vataman, E., Grigorică, L., Sisakian, H. S., Glavaš, D., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1074 · Cited by 18
“6,7 In HFpEF, exercise and caloric restriction 8 and glucagon-like peptide-1 agonists in obesity with concurrent HFpEF 9,10 may be effective.”
Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches
Khunti, K., Papamargaritis, D., Aroda, V. R., Anjana, R. M., & Kashyap, S. R. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00134-2 · Cited by 22
Ard, J. D., Lee, C. J., Gudzune, K. A., Addison, B., Lingvay, I., Cao, D., Mast, C. J., Stefański, A., Falcón, B. L., & Mojdami, D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16554 · Cited by 26
“10 Additionally, treatment with tirzepatide has been associated with clinically meaningful change in sleep-disordered breathing 11 and lower risk of progression to type 2 diabetes.”
Rodrigues, M. M., & Falcão, L. M. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133182 · Cited by 20
Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
“Obesity-related diseases and conditions that benefit from this weight-loss magnitude include metabolic dysfunction–associated steatohepatitis with moderate- to-severe fibrosis, 7 46 heart failure with preserved ejection fraction, 47 48 and knee osteoarthritis.”
Hankosky, E. R., Lebrec, J., Lee, C. J., Dimitriadis, G. K., Jouravskaya, I., Stefanski, A., & Garvey, W. T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70143 · Cited by 17
“29,45,46 We observed an increase in the predicted cardiovascular risk at week 176 in the placebo arm, likely due to the natural progression of obesity and prediabetes, despite the lifestyle interventions that participants underwent as part of the trial.”
Okuno, T., Kagami, K., Harada, T., Hoshiga, M., Ishii, H., & Obokata, M. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0214 · Cited by 20
Okazaki, R. A., Rizvi, S. H. M., Lyons, R., Behrooz, L., & Hamburg, N. M. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00793.2024 · Cited by 19
Zheng, W., Qi, Q., Li, J., He, C., & Fan, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01917-z · Cited by 19
Vaduganathan, M., Claggett, B. L., Chatur, S., Desai, A. S., Jhund, P. S., Vardeny, O., Merkely, B. P., Martínez, F. A., Colet, J. C., Saraiva, J. F. K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04037-3 · Cited by 20
“In fact, three recent trials with sample sizes of approximately 500–750 participants have demonstrated clinical benefits 25–27 .”
Shokravi, A., Seth, J., Lu, N., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00248-2 · Cited by 17
Hankosky, E. R., Desai, K. R., Chinthammit, C., Grabner, M., Stockbower, G. E., He, X., Mojdami, D., Wenziger, C. M., & Gibble, T. H. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101636 · Cited by 21
Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review
Liu, Z., Weeldreyer, N. R., & Angadi, S. S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf335 · Cited by 21
Pop-Busui, R., Rasmussen, S. M., Deanfield, J. E., Buse, J. B., Marx, N., Mulvagh, S. L., Inzucchi, S. E., Mann, J. F. E., Emerson, S. S., Poulter, N. R., et al. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.7774 · Cited by 18
López-Jiménez, F. A., Cesare, M. D., Powis, J., Shrikhande, S. S., Adeoye, M., Codato, E., Zhou, B., Bixby, H., Evans, N. R., Lara-Breitinger, K. M., et al. (2025) · Global Heart · doi:10.5334/gh.1451 · Cited by 19
Allahwala, M. A., Marathe, C. S., Nelson, A. J., Psaltis, P. J., & Marathe, J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.005 · Cited by 17
Management of Peripheral Artery Disease in Adults With Diabetes: 2025 ACC Scientific Statement
Das, S. R., Bonaca, M. P., Creager, M. A., Maruthur, N. M., Nordanstig, J., Pop‐Busui, R., & Ujueta, F. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.11.027 · Cited by 30
Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16
“Weight loss is likely to improve quality of life and exercise tolerance in GLP-1 RA–treated patients [63, 139, 140], eventually leading to an enhanced ability to engage in daily physical activity and rehabilitation programs.”
InfluentialKaul, S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.036 · Cited by 19
SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes
Liakos, A., Karagiannis, T., Avgerinos, I., & Bekiari, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-025-01616-z · Cited by 21
“…have thus far been demonstrated only with specific agents such as subcutaneous semaglutide [25 ], the first in class dual glucose-dependent insulinotro - pic polypeptide/GLP-1 receptor agonist tirzepatide [26], as well as the nonsteroidal mineralocorticoid receptor antagonist finerenone [ 27 ].”
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024
Tamargo, J. L., Agewall, S., Ambrosio, G., Borghi, C., Cerbai, E., Dan, G. A., Drexel, H., Ferdinándy, P., Grove, E. L., Klingenberg, R., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf012 · Cited by 18
Heart failure and obesity: novel insights leading to new treatment paradigms
Meems, L. M. G., van Veldhuisen, D. J., Sattar, N. A., & Lee, M. M. Y. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01190-7 · Cited by 20
“Tirzepatide improved HF outcomes, with a 46% reduction in worsening HF events 30 .”
InfluentialCauses and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
Christensen, S. M., & Nelson, C. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100175 · Cited by 21
“Other obesity trials of semaglutide and tirzepatide show clinical improvement for adults with conditions such as heart failure [97 – 100], prediabetes [74,101,102], and knee osteoarthritis [103].”
Hegedűs, Z. I., Jakab, M. E., Gergely, T. G., Sayour, N. V., Kovács, A., Antal, S., Kovács, T., Ferdinándy, P., Varga, Z. V., & Tóth, V. É. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02806-5 · Cited by 18
“The recent SUMMIT trial investigating tirzepatide therapy in patients with HFpEF provided the first evidence of an improved cardiovascular outcome (a composite of death from cardiovascular causes or worsening heart failure)[11].”
Peikert, A., Vacca, A., Norata, G. D., Schiattarella, G. G., & Osto, E. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.012674 · Cited by 22
“78,79 Notably, reductions in markers of systemic inflammation observed with both GLP-1 and combined GLP-1/ GIP receptor agonism in the SELECT, STEP-HFpEF program, and SUMMIT trials, supported by experimental and clinical evidence of an attenuated immune response with incretin-based obesity…”
Physiology and clinical applications of GIP
Yamane, S., Harada, N., & Inagaki, N. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej25-0087 · Cited by 16
“The SUMMIT trial demonstrated that treatment with tirzepatide reduced the risk of a composite of cardiovascular-related deaths or worsening heart failure, compared with placebo, and improved the health of patients with heart failure with preserved ejection fraction and obesity [147].”
Luu, S., Chan, D. E. C. Y., Marshall, N. S., Phillips, C. L., Grunstein, R. R., & Yee, B. J. (2025) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2025.102169 · Cited by 17
GLP-1 Receptor Agonists in Heart Failure
Rahmani, A. R., Dhaliwal, S., Pastena, P., Kazakov, E., Jayaseelan, K., & Kalogeropoulos, A. P. (2025) · Biomolecules · doi:10.3390/biom15101403 · Cited by 19
“By contrast, the consistent benefits observed in STEP-HFpEF [14,15] and SUMMIT [35] underscore the therapeutic potential of GLP-1 receptor agonists in obesity-related HFpEF and highlight the need for future trials to explore their role across broader HF phenotypes.”
InfluentialPharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 27
“…individuals with BMI ≥ 30 kg/m 2 and HF with LVEF ≥ 50% enrolled in the SUMMIT RCT, tirzepatide improved HF-related health status and reduced the rate of cardiovascular death or a worsening HF event by 38% (48), although number of events was relatively low (36 with tirzepatide and 56 with placebo).”
Mendieta, G., Ridker, P. M., Borlaug, B. A., Ducharme, A., Lam, C. S. P., Voors, A. A., Auerbach, P., Čikeš, M., Fudim, M., Hvelplund, A., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag153 · Cited by 20
“In STEP-HFpEF, 71% of participants with obesity-related HFpEF had an hsCRP ≥ 2 mg/l. 32 In SUMMIT, the mean hsCRP was 5.8 mg/dl. 33 While levels of inflammatory markers are certainly elevated in HFpEF, whether these are biomarkers of advanced disease or ongoing drivers of HF, which can be modified,…”
InfluentialSelf-citationThe evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“…receptor (GIPR)– GLP1R co-agonist, has shown greater weight-lowering efficacy in people with obesity than semaglutide, reaching mean placebo-corrected weight loss in the region of 15–20% 14,18 , and additional benefits on certain obesity-related complications 19,20 and diabetes prevention 21 .”
Bansal, B., Lajeunesse‐Trempe, F., Keshvani, N., Lavie, C. J., & Pandey, A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.04.012 · Cited by 28
Obesity and heart failure: exploring the cardiometabolic axis
Rayner, J. J., Abdesselam, I., Pan, J., Lewis, A., & Rider, O. J. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf090 · Cited by 17
“12,13 However, an increasing body of evidence suggests that there are numerous benefits to managing obesity and its associated complications in heart failure, 14,15 and these exciting new developments suggest that we may finally be on the brink of a revolution in managing obesity in heart failure.”
Monzo, L., Savarese, G., Müllens, W., Abdin, A., Bozkurt, B., Chioncel, O. D., Hadidi, S. E., Gorter, T. M., Inciardi, R. M., Petrie, M. C., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70082 · Cited by 17
“3 Notably, in obese HF patients circulating natriuretic peptide levels are often lower than expected for the degree of haemodynamic congestion, complicating diagnosis and risk stratification.”
Aging and metabolism in HFpEF: Pathophysiology and therapeutic implications
Ye, M., Feng, S., Xu, Z., He, W., Liu, C., & Zhu, W. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156460 · Cited by 16
Kittleson, M. D., Panjrath, G. S., Bates, K., Breathett, K. K., Dixon, D. L., Januzzi, J. L., & Mohammed, S. F. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.06.018 · Cited by 25
Cunningham, J. W., Chatur, S., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., Esperón, G. L., Lam, C. S. P., Sato, N., Senni, M., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0016 · Cited by 16
Fitch, A., Gigliotti, L., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100205 · Cited by 14
“Studies have demonstrated cardiovascular benefits with GLP-1 based therapies in patients with pre-existing cardiovascular disease or cardiovascular risk factors [29,43], including patients with heart failure with preserved ejection fraction and obesity [44,45].”
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Cardiometabolic Dysregulation and Heart Failure
Ashfield, S., & Ojha, U. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm38504 · Cited by 15
“Recently, Packer and colleagues [32] also reported that in patients with HFpEF and a BMI of greater than 30, treatment with tirzepartide significantly reduced the risk of death from cardiovascular disease and HF.”
Physiologic Phenotyping of Responses to Exercise and Activity in Heart Failure
Lewis, G. D., Tada, A., Landsteiner, I., & Borlaug, B. A. (2025) · Circulation Research · doi:10.1161/circresaha.125.325534 · Cited by 18
Self-citationKetema, E. B., & Lopaschuk, G. D. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.01.029 · Cited by 19
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Gonzales-Uribe, A., Ruiz-Cortez, R., Silva, N. C., Olivero, L. J., Agarwal, R., Castillo, S. A., Garcia-Geng, A., Lyu, X., Mendoza‐Quispe, D., Becerra-Gonzales, V. G., et al. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02710-8 · Cited by 15
“[23], and Wallner et al .”
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“Similarly, tirzepatide reduced HF-related events and improved physical performance in adults with HFpEF (SUMMIT trial) [29], decreased the apnea-hypopnea index in obstructive sleep apnea (OSA) (SURMOUNT-OSA trial) [30], leading to FDA approval for moderate-to-severe OSA in adults with obesity [31],…”
Effect of GLP1 Agonists on Reproduction
Couldwell, M., Tidwell, A. J., & Taylor, A. E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf401 · Cited by 16
Current Treatment of Heart Failure with Preserved Ejection Fraction
Riccardi, M., D’Elia, E., Lombardi, C., Savarese, G., Gori, M., Oliva, F. G., Volterrani, M., Senni, M., Metra, M., & Inciardi, R. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155406 · Cited by 13
Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea
D’Annibale, D. A., Mimoto, M. S., McCowen, K. C., & Malhotra, A. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001208 · Cited by 13
Gu, S. (2026) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s556918 · Cited by 15
“10,29 Tirzepatide’s mechanism of action could induce a state of passive calorie restriction and malnutrition, which may cause metabolic and digestive disturbances and even neuropsychiatric effects, such as anorexia nervosa, sleep disorder, muscle atrophy and Wernicke’s encephalopathy (indicating…”
GLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 14
Parizad, R., Hatwal, J., Sadeghi, M. T., Brar, A. S., Desai, R., Batta, A., & Mohan, B. (2026) · Vascular Health and Risk Management · doi:10.2147/vhrm.s578698 · Cited by 14
“103,104 These findings underscore the heterogeneity of HFpEF and the potential for targeted metabolic and anti-fibrotic interventions, although no single agent is universally disease-modifying across all phenotypes.”
Greene, S. J., Butler, J., & Fonarow, G. C. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0038 · Cited by 13
Visceral obesity and HFpEF: targets and therapeutic opportunities
Li, Y., Lin, Z., & Li, Y. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.02.005 · Cited by 13
Optimizing Body Composition During Weight Loss: The Role of Amino Acid Supplementation
Cannavaro, D., Leva, F., Caturano, A., Berra, C., Bonfrate, L., & Conte, C. (2025) · Nutrients · doi:10.3390/nu17122000 · Cited by 15
SNAITH, J. R., Narongkiatikhun, P., Bjornstad, P., Greenfield, J. R., & Tommerdahl, K. L. (2025) · Diabetes Care · doi:10.2337/dci25-0015 · Cited by 19
Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus
Martínez, J. J. G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030678 · Cited by 15
Theodorakis, N., Nikolaou, M., & Krentz, A. J. (2025) · Biomolecules · doi:10.3390/biom15030373 · Cited by 15
“These findings suggest that tirzepatide may reduce the risk of cardiovascular events in patients with HFpEF and obesity [83].”
Ebong, I., Gill, A., Appiah, D., & Mauricio, R. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10528-9 · Cited by 17
Chi, K.-Y., Song, J., Desphande, S., Lee, P., Soni, A., Gonzales-Uribe, A., Lessa, Y., Morgan, A. A., Chang, Y., Lin, Y.-S., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.17541 · Cited by 14
Wu, J., Lin, Y., Hsu, W., Liu, T., Tsai, Y., Huang, P., Chuang, M., Yu, T., & Lai, C. (2025) · Hepatology International · doi:10.1007/s12072-025-10857-9 · Cited by 12
“The primary outcome was a composite endpoint including all-cause mortality, major adverse cardiovascular event, major adverse kidney event, and major adverse liver event heart failure, T2D, and obstructive sleep apnea [22–25].”
Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction
Packer, M., Testani, J. M., Butler, J., Zannad, F. M., Lam, C. S. P., Vaduganathan, M., Fang, J. C., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.086 · Cited by 15
Self-citationVirani, S., Zieroth, S. R., Aleksova, N., Anderson, K., Clarke, B., Ducharme, A., Ezekowitz, J. A., Foroutan, F., Giannetti, N., Jain, R., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.027 · Cited by 34
RetractedObesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
Khalil, I., Islam, M. R., Kamrul-Hasan, A. B. M., Nagendra, L., Promi, S. A., Sayed, M. A., Rahman, M. A., Sultana, N., Tasmi, N. A., Das, M., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.005 · Cited by 13
Steenackers, N., Toumassian, J., Deleus, E., Mertens, A. C., Lannoo, M., Pazmiño, S., van Laar, A. D. E., der Schueren, B. V., & Vangoitsenhoven, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569468 · Cited by 21
Risk and temporal trends of heart failure subtypes in rheumatoid arthritis
Johnson, T. M., Yang, Y., Roul, P., Frideres, H., Baker, J. F., Sauer, B. C., Cannon, G. W., Kunkel, G. A., Bookani, K. R., Mikuls, T. R., et al. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152816 · Cited by 13
Wadden, T., Oquendo, M. A., Kushner, R. F., Cao, D., Karanikas, C. A., Kechter, A., & Murphy, M. A. (2026) · Obesity · doi:10.1002/oby.70122 · Cited by 16
Podder, D., Stala, O., Miah, A., Agyapong, A., Moore, M. E., Hirani, R., Diegisser, D., Garcia, V. G., & Etienne, M. (2026) · Diabetology · doi:10.3390/diabetology7030046 · Cited by 19
Fuerlinger, A., Stockner, A., Sedej, S., & Abdellatif, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02566-8 · Cited by 12
Jiang, H., Wattanachayakul, P., Kittipibul, V., Nicolsen, E., McVeigh, T., Kamneva, O., & Fudim, M. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15308 · Cited by 11
Alhomoud, I. S., Wheeler, S. E., & Dixon, D. L. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0038 · Cited by 14
Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?
Dreher, L., Kylies, D., Danser, A. H. J., & Wenzel, U. O. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25112 · Cited by 13
Bauersachs, J. K., Kato, E. T., & Rangaswami, J. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15345 · Cited by 12
Borlaug, B. A., Zile, M. R., Kramer, C. M., Litwin, S. E., Ye, W., Ou, Y., Hurt, K. C., Murakami, M., & Packer, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf663 · Cited by 11
Self-citationPharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
Metadata
- Authors
- Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., & Borlaug, B. A.
- Affiliations
- Cleveland Clinic (US)
- From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.); the Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville (C.M.K.); Flourish Research, Boca Raton, FL (S.J.B.); the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland (V.M.); the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China (J.G.); Eli Lilly, Indianapolis (G.J.W., Y.O., M.C.B., K.C.H., M.M.); and the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-01-30
- Volume
- 392
- Issue
- 5
- Pages
- 427-437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404437149
- Semantic Scholar
- aeedfcfb5543cef26bd4f4576e1c5a59b4d2424f
- Cited by
- 1,009
- References
- 30
- Citations by year
- 2026: 496 · 2025: 494
- FWCI
- 303.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company (N/A)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, heart failure with preserved ejection fraction, obesity, GIP/GLP-1 receptor agonist, weight loss, cardiovascular mortality, worsening heart failure, Kansas City Cardiomyopathy Questionnaire, quality of life, body mass index, GLP-1 receptor agonists, GIP receptor agonist, cardiovascular outcomes, weight loss treatment, heart failure with reduced ejection fraction
- MeSH terms
- Tirzepatide, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Obesity, Quality of Life, Stroke Volume, Weight Loss, Body Mass Index, Treatment Outcome, Glucagon-Like Peptide 1, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.